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Abstract
The synthesis and characterization oftwo Pt(ll) complexes with the isomeric ligands 4,5-dihydro-5-oxo-
1,2,4]triazolo-[ 1,5-a]pyrimidine (5HtpO) and 4,7-dihydro-7-oxo-[ 1,2,4]-triazolo-[ 1,5-a]pyrimidine (7HtpO) are
described, as well as a Ru(lll) complex with 7HtpO. The crystal structure of cis-[PtCl,_(7HtpO),_].2H20 has been
solved by X-ray diffraction analysis. In vitro activity of the new isolated complexes against the epimastigote
form of 7". cruzi, procyclic form of 7". b. brucei and promastigote form of L. donnovani and P. characias has
also been studied. The three complexes markedly affect the growth of the parasites and none of them shows
cytotoxicity against macrophage of the J774.2 line at the heaviest dosages used.
INTRODUCTION
The members of the family Trypanosomatidae are the etiological agents of numerous diseases which
afflict not only humans but also animals and plants. Examples include American trypanosomiasis, or Chagas’
disease, which is caused by Trypanosoma cruzi, African trypanosomiasis, caused by two strains of
Trypanosoma brucei,’-I Leishmania donovani, inflicting visceral leishmaniasis or Kala-azar and Ph)’tomonas
characias, which attacks the lactiferous plant Euphorbia chctracias, resulting in defoliation, deformation,
chlorosis and atrophy,
t3 Even in the 21st century, despite the development of efficient drugs against these
protozoan parasites, the eradication of such diseases remains seriously deficient. The administration of these
drugs entails a number of drawbacks, such as variable efficacy, normally long treatment often with toxic side-
effects, parenteral administration for some diseases and the appearance of resistant Stl’ains.
t4 Another problem
is that the development of new drugs requires heavy financial investment from the industry and the areas most
in need of these drugs are economically depressed, and therefore the industry takes little interest in developing
these drugs. The search for new compounds is, therefore, urgent.
Choosing [1,2,4]triazolo[1,5-a]pyrimidine derivatives for our studies is based on the fact that these
ligands could be considered as mimetic of purines. Different researchers have studied them as chemotherapeutic
agents, finding different interesting properties, such as the growth inhibition of some microorganisms. With
regard to their antitumoural activity, studies have been made for various cell lines such as the breast cancer
MDA/MB-231 .8 Their potential in the treatment ofneurodegenerative disorders such as Parkinson’s disease has
also been tested.
9
The coordination chemistry of these ligands has been extensively studied in recent years. They have,
as potential donors, three endocyclic nitrogen atoms at positions 1, 3 and 4, N(3) being the preferred metal
binding site in the monodentate mode (see Figure forthe numbering scheme used for these ligands). Another
possibility found in several cases is the bridging N(3)-N(4) mode giving dinuclear metal complexes.
-’’3
We have shown, in previous works, the biological activity of some metal complexes of
[1,2,4]triazolo[1,5-a]pyrimidine derivatives. In this way, we have recently tested the effect of several metal
complexes of 4,7-dihydro-5-methyl-7-oxo [1,2,4]-triazolo-[1,5-a]pyrimidine (HmtpO),-, against" Phytomonas
Staheli (promastigote form), Trypanosoma cruziand Leishmania donovani.
4 ome ofthem proved capable
of inhibiting the growth of these flagellates at dosages of50 IaM after 24 h of activity, inhibiting the synthesis
of macromolecules (DNA, RNA and proteins) by the parasites and inducing severe damage in their
u trastructure.
4)
With this new work, we seek to advance one step further in the development of effective chemotherapy
against members of the family Trypanosomatidae by testing three newly synthesized metal complexes (two of
Pt(II) and one of Ru(III)) oftriazolopyrimidine derivatives on the epimastigote forms of T. cruzi, procyclic
forms of T. b. brucei and promastigote forms of L. donovani and P. characias, determining the effect of these
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complexes on the in vitro growth of the parasites as well as the possible toxicity of these treatments at
macrophage level.
MATERIALS AND METHODS
Chemicals
Hydrated ruthenium(Ill)chloride was supplied by Johnson Matthey and potassium tetrachloroplatinate(II)
by Sigma-Aldrich Chem. and were used without further purification. The isomeric iigands 4,5-dihydro-5-
oxo[l,2,4]triazolo[ 1,5-a]pyrimidine (SHtpO) and 4,7-dihydro-7-oxo 1,2,4]triazolo[ 1,5-a]pyrimidine (7HtpO)
were synthesized using previously described methods.
6
Synthesis ofthe metal complexes
The platinum(II) complexes cis-[PtCl.(7HtpO)z].2H:O (I) and [PtCI,(5HtpO)z].2H_,O (2) were prepared
by mixing two solutions in HCI 1N, 10 mL each, the first one containing 2 mmol of Kz[PtCiq] and the second
one containing 4 mmol of 7HtpO or 5HtpO. The resulting solutions were left to evaporate at room temperature
and yellow crystals, suitable for X-ray analysis in the case of 1, were obtained after a few days, whereupon they
were collected by filtration and air dried. Calculated elemental analysis for C0H_ON8CI:Pt: C, 20.92; H, 2.11
N, 19.51%. Found: C. 20.75; H, 2.09; N. 19.24% (1) and C, 20.91; H, 2.11; N. 19.35% (2).
The ruthenium(Ill) complex RuCI3(7HtpO),.2H:O (3) was obtained by mixing two solutions, 25 mL
each, one containing 6 mmol of ruthenium(lII) chloride in water an the other containing 6 mmol of 7HtpO in
IN HCI. The resulting solution was heated and stirred for lb. After cooling a brown dark precipitatewas isolated
by filtration, washed with ethanol and air dried. Calculated elemental analysis for C0HzO4NsCIRu: C, 23.29;
H, 2.35; N, 21.75%. Found for 3: C, 23.01; H, 2.68; N, 21.65%.
Table 1. Crystal data for
Molecular formula C0H zCI2NsOPt
Formula weight 574.27
Crystal system Monoclinic
Space group P 2 /n
a, A 10.046(2)
b,/ 13.354(3)
c, ]k 13.128(3)
b, 112.08(3)
V, ,3 1631.9(6)
Z 4
Dc, g cm
3 2.337
m(MoKo0, mm 8.962
Unique reflections 3734
wR2 0.1316
R (F>4cy(F)) .0j0475 Final AF, eA
-3 .663 6.850
Deposition number CCDC 158297
Instrumentation
Elemental analysis were performed in a Fisons Instruments EA- 1008 analyzer and H-NMR spectra were
recorded for DMSO-d solutions in a BrukerAM300 equipment, both at the Centre of Scientific Instrumentation
of the University of Granada.
X-ray determination
A colourless prismatic single crystal of 0.3 x 0.05 x 0.02 mm was mounted in a Nonius Kappa CCD
diffractometer with MoKo radiation (X 0.71073 A). The crystal data and the most relevant experimental
parameters are reported in Table 1. Structure solution and refinement was performed by standard crystallographic
procedure. The program SHELX-97
7) was used for the refinement.
Biological Assays
The strain of 7/. cruzi was isolated in 1972 from a human clinical case in Venezuela (Malariology
Institute, Maracay, Venezuela). Epimastigote forms were obtained in biphasic medium (NNN supplementedwith
MEM and 20% IFBS) and afterwards reseeded in a monophasic culture (LTM), following the method of Ruiz-
Perez et al. The procyclic forms of T. b. brucei used in the experiment came fi’om a stock 120.499, kindly
given by Fred R. Opperdoes, from the Search Unit for Tropical Diseases at the Internationallnstitute ofCell and
Molecular Pathology in Brussels (Belgium). These forms were cultured in vitro at 28C in plastic Roux flasks,
seeding an inoculate of 5 x 10 cells per mL into 3 mL of culture medium (SDM-79 with 10% inactivated SB F
added).
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The L. donovani strain L133 (Leishmania Reference Centre, Jerusalem) was maintained by culture in
NNN medium (GIBCO) and 20% IFBS (LTM). Afterwards, promastigote forms were obtained by reseeding in
rnonophasic culture, TC-199 (GIBCO) supplemented with 30% IFBS. P. characias, originally isolated from
Euphorbia characias, was generously providedby Dr. M.Dollet. The flagellates were cultured in Grace’s
medium at 28C, following Fernindez-Becerra et al
9)
All the forms were taken at the exponential growth phase, centrifuged at 1500 g for 10 rain and 4C and
resuspended in medium. The number ofparasites was quantifiedusing an haemocytometer chamber and adjusted
to 10Vml.
Mouse macrophages J-774A.I (ECACC85011428) were cultured in RPMI 1640 medium (GIBCO)
supplemented with 2raM L-glutamine and 10% IFBS at pH 7.2.
The three metal complexes assayed were dissolved in DMSO, and tested at 1, 20, 50 and 100 tM in
culture medium with 0.01% DMSO final concentration. Controls and assays were prepared including 0.01%
DMSO. Assays were performed in Roux flasks with a final volume of 10 ml and an original density of lx I0
cells/ml. The cultures were maintained for 24, 48 and 72 h at 28C. For each time and dosage tested, five
replicates and corresponding controls were quantified using a Neubauer chamber.
RESULTS AND DISCUSSION
NMR spectra
The H-NMR spectra of DMSO-d6 solutions of both platinum complexes, if recorded immediately after
dissolving the compounds, display a set of signals of a majoritary species, presurniblely the same present at the
solid state. The positions (in ppm.) and assignments of the signals are as follows:
Compound 1:6.10 (d, H(6)), 8.08 (d, H(5)), 8.56 (s, H(2)), J(H(5)-H(6)) 7.6 Hz. H(4) not observed.
Compound 2:6.52 (d, H(6)), 8.64 (s, H(2)), 8.81 (d, H(7)), J(H(6)-H(7)) 7.4 Hz. H(4) not observed.
All these signals are downfield shifted with respect to their positions in the free ligands,/the highest
shift being that of H(2), in agreement with N(3) coordination to the platinum atom.
If the DMSO-d6 solutions ofthe complexes are left for several hours and spectra are taken again, we can
see that the intensity of the signals assigned to the Pt complexes decrease at the same time that new signals
appear and grow, at positions identical to those of the free ligands. This indicate us that the complexes are
unstable in DMSO solution, the solvent probablydisplacing the triazolopyrimidineligand fi’om the coordination
sphere of the metal atom. This decomposition is almost complete after 24 hours.
Crystal structure of
The molecular structure of 1, depicted in Figure 1, is almost identical to that of the analogous compound
with the iigand HmtpO2 which differs of 7HtpO by the presence of a methyl group at position 5. Both
compounds are not, however, crystallographically isostructural.
The platinum atom is in a typical square-planar environment (see distances and angles in Table 2),
coordinated by two chloride anions and two N3-bonded 7HtpO ligands in a cis disposition. The relative
orientation of the ligands is head-head, stabilized by the presence of a water molecule (OIW) which acts as
acceptor of hydrogen bonds of the N4-H groups of both iigands. The second water molecule also contributes to
the stabilization of the complex by the formation of hydrogen bonds with O1W and one ofthe chloride ligands.
Table 2. Selected distances (A) and angles (1) for
Bond distances Bond angles
Pt-Cl 2.298(2) CI 1-Pt-CI2 92.10(7)
Pt-C 12 2.278(2) Cl I-Pt-N3A 91.7(2)
Pt-N3A 2.025(7) C I1-Pt-N3B 177.2(2)
Pt-N3B 2.008(6) C 12-Pt-N3A 175.2(2)
CI2-Pt-N3B 88.4(2)
Hydrogen bonds N3A-Pt-N3B 88.0(3)
N4A...O 1W 2.808(10)
N4B...O1W 2.774(9)
O1W...O2W 2.811(12)
O1W...O7B 2.751(8)
O2W...Cl2 3.093(9)
See legend of Table 3.
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Antiparasitary tests
The three triazolopyrimidine derivatives markedly affect the growth of the epimastigotes of T. cruzi,
procyclic forms T. b. brucei and promastigotes of L. donovani cultured in vitro. The results are reflected in
Tables 3, 4 and 5. This inhibition is highest for compound 1. On the other hand, in the case of the growth of
P. characias cells, 3 proved the most inhibitory, whereas and 2 did not cause any significant growth
inhibition, apparently due to the metabolic differences between the promastigote forms of P. characias and the
other three trypanosomatids.
None of these derivatives presented cytotoxicity against rnacrophages ofthe J774.2 line (Table 6), at the
heaviest dosages used (50 and 100 btM), in agreementwith observations and studies by other authorsfor different
pyrimidine derivatives.
2/
C6 C5B
C7.
CSA
C6A
C7A
O7A
C12 CI1
Figure Molecular structure ofcompound 1, as deduced from X-ray data. Non
hydrogen atoms are shown as thermal ellipsoids at the 50% probability level.
TABLE 3: Percentage of growth inhibition caused by compound 1.
t,tM 20 laM 50 laM,
24 48 72 24 48 72 24 48 72
T. cruzi 15 10 8 30* 33* 11 42 54**
T. brucei brucei 18 37* 16 39* 47** 7 50** 74**
L. donovani 12 25 37* 16 36* 47** 38* 48** 56**
P.characias 16 7 20 5
100 gM
24 48 72
26 66** 81"*
30* 61"* 85**
52** 62** 94**
11 8
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The results are expressed in percentages of cell-growth inhibition (n=5). Significant differences between control
and treatment cells were found according to the Newman-Keuls test. * P< 0.05. ** P< 0.025.
TABLE 4: Percentage of growth inhibition caused by compound 2.
llaM] [20tM] [50M1 O0M]
24 48 72 24 48 72 24 48 72 24 48 72
T.cruzi 15 12 18 23 25 38* 17 29* 46** 30* 39* 59**
T. brucei brucei 10 13 19 7 17 38* 8 21 48** 21 50** 70**
L. donovani 7 15 32* 7 18 36* 22 35* 56** 32* 45** 74**
P. characias 10 2 10 21 25
TABLE 5+." Percentage of growth inhibition caused by compound 3 (See legend of Table 3).
lgM] [20gM] [501aM] 100tM]
24 48 72 24 48 72 24 48 72 24 48 72
T. cruzi 12 18 24 14 20 31" 17 27* 40** 28* 43** 61"*
T. brucei brucei 22 23 19 27* 29* 32* 33* 35* 41"* 36* 46** 61"*
L. donovani 8 11 16 14 15 34* 27* 33* 43** 36* 43** 59**
P. characias 3 9 25 14 22 29* 15 29* 48** 24 33" 56**
TABLE 6: Action of the complexes against mouse macrophage J-7740 cell line (Percentage of cell viability).
24 h. 48 h. 72 h.
50 gM 100 gM 50 gM 100 gM 50 laM 100
Control 76.29% 93.45% 82.88%
65.00% 68.57% 95.83% 90.20% 83.16% 87.38%
2 75.28% 95.45% 96.74% 93.39% 90.55% 90.91%
3 78.68% 80.91% 94.37% 89.16% 81.56% 85.61%
Number of experiments: 3.
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